Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

The biotech's Rasonque is already available for prescription.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at fool.com →

More in Finance & Markets

More from Friday 28 August →